Effects of inulin-type fructans, galacto-oligosaccharides and related synbiotics on inflammatory markers in adult patients with overweight or obesity: A systematic review

Clinical Nutrition

Volumn 36, Issue 5, 2017, Pages 1197-1206

  Fernandes, Ricardo ^a   do Rosario, Vinicius A ^a   Mocellin, Michel C ^a   Kuntz, Marilyn G F ^a   Trindade, Erasmo B S M ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Obesity; Overweight; Prebiotics; Synbiotics; Systematic review

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYTOKINE; FRUCTAN; GALACTOSE OLIGOSACCHARIDE; INULIN; INULIN TYPE FRUCTAN DERIVATIVE; SYNBIOTIC AGENT; UNCLASSIFIED DRUG; ENDOTOXIN; OLIGOSACCHARIDE; PREBIOTIC AGENT;

CYTOKINE PRODUCTION; DATA BASE; HUMAN; IMMUNOMODULATION; INFLAMMATION; METHODOLOGY; NUTRITIONAL ASSESSMENT; NUTRITIONAL HEALTH; OBESITY; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; PROTEIN BLOOD LEVEL; REVIEW; SYSTEMATIC REVIEW; VALIDATION STUDY; ADULT; BLOOD; METABOLISM; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY AND SPECIFICITY;

ADULT; BIOMARKERS; C-REACTIVE PROTEIN; CYTOKINES; ENDOTOXINS; HUMANS; INFLAMMATION; INULIN; OBESITY; OLIGOSACCHARIDES; OVERWEIGHT; PREBIOTICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SENSITIVITY AND SPECIFICITY; SYNBIOTICS;

EID: 85008929926     PISSN: 02615614     EISSN: 15321983     Source Type: Journal    
DOI: 10.1016/j.clnu.2016.10.003     Document Type: Review

References (48)

1. Galic, S., Oakhill, J.S., Steinberg, G.R., Adipose tissue as an endocrine organ. Mol Cell Endocrinol 316:2 (2010), 129–139, 10.1016/j.mce.2009.08.018.
2. Johnson, A.R., Milner, J.J., Makowski, L., The inflammation highway: metabolism accelerates inflammatory traffic in obesity. Immunol Rev 249:1 (2012), 218–238, 10.1111/j.1600-065X.2012.01151.x.
3. World Health Organization, Obesity and overweight. Fact sheet nº 311. 2015 [Accessed 8 December 2015] at http://www.who.int/mediacentre/factsheets/fs311/en.
4. Turnbaugh, P.J., Hamady, M., Yatsunenko, T., Cantarel, B.L., Duncan, A., Ley, R.E., et al. A core gut microbiome in obese and lean twins. Nature 457:7228 (2009), 480–484.
5. Schwiertz, A., Taras, D., Schäfer, K., Beijer, S., Bos, N.A., Donus, C., et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity 18:1 (2010), 190–195, 10.1038/oby.2009.167 (Silver Spring).
6. Le Chatelier, E., Nielsen, T., Qin, J., Prifti, E., Hildebrand, F., Falony, G., et al. Richness of human gut microbiome correlates with metabolic markers. Nature 500:7464 (2013), 541–546, 10.1038/nature12506.
7. Kallus, S.J., Brandt, L.J., The intestinal microbiota and obesity. J Clin Gastroenterol 46:1 (2012), 16–24, 10.1097/MCG.0b013e31823711fd.
8. Cox, A.J., West, N.P., Cripps, A.W., Obesity, inflammation, and the gut microbiota. Lancet Diabetes Endocrinol 3:3 (2015), 207–215, 10.1016/S2213-8587(14)70134-2.
9. Moreno-Navarrete, J.M., Sabater, M., Ortega, F., Ricart, W., Fernández-Real, J.M., Circulating zonulin, a marker of intestinal permeability, is increased in association with obesity-associated insulin resistance. PLoS One, 7(5), 2012, e37160, 10.1371/journal.pone.0037160.
10. Cani, P.D., Amar, J., Iglesias, M.A., Poggi, M., Knauf, C., Bastelica, D., et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56:7 (2007), 1761–1772, 10.2337/db06-1491.
11. Cani, P.D., Bibiloni, R., Knauf, C., Waget, A., Neyrinck, A.M., Delzenne, N.M., et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57:6 (2008), 1470–1481, 10.2337/db07-1403.
12. Dehghan, P., Pourghassem Gargari, B., Asghari Jafar-abadi, M., Oligofructose-enriched inulin improves some inflammatory markers and metabolic endotoxemia in women with type 2 diabetes mellitus: a randomized controlled clinical trial. Nutrition 30:4 (2014), 418–423, 10.1016/j.nut.2013.09.005.
13. Dehghan, P., Gargari, B.P., Jafar-Abadi, M.A., Aliasgharzadeh, A., Inulin controls inflammation and metabolic endotoxemia in women with type 2 diabetes mellitus: a randomized-controlled clinical trial. Int J Food Sci Nutr 65:1 (2014), 117–123, 10.3109/09637486.2013.836738.
14. Malaguarnera, M., Vacante, M., Antic, T., Giordano, M., Chisari, G., Acquaviva, R., et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci 57:2 (2012), 545–553, 10.1007/s10620-011-1887-4.
15. Beserra, B.T., Fernandes, R., do Rosario, V.A., Mocellin, M.C., Kuntz, M.G., Trindade, E.B., A systematic review and meta-analysis of the prebiotics and synbiotics effects on glycaemia, insulin concentrations and lipid parameters in adult patients with overweight or obesity. Clin Nutr 34:5 (2015), 845–858, 10.1016/j.clnu.2014.10.004.
16. Roberfroid, M., Gibson, G.R., Hoyles, L., McCartney, A.L., Rastall, R., Rowland, I., et al. Prebiotic effects: metabolic and health benefits. Br J Nutr 2:104 Suppl (2010), S1–S63, 10.1017/S0007114510003363.
17. Guarner, F., Khan, A.G., Garisch, J., Eliakim, R., Gangl, A., Thomson, A., et al. World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics october 2011. J Clin Gastroenterol 46:6 (2012), 468–481, 10.1097/MCG.0b013e3182549092.
18. Gargari, B.P., Namazi, N., Khalili, M., Sarmadi, B., Jafarabadi, M.A., Dehghan, P., Is there any place for resistant starch, as alimentary prebiotic, for patients with type 2 diabetes?. Complement Ther Med 23:6 (2015 Dec), 810–815, 10.1016/j.ctim.2015.09.005.
19. Aliasgharzadeh, A., Dehghan, P., Gargari, B.P., Asghari-Jafarabadi, M., Resistant dextrin, as a prebiotic, improves insulin resistance and inflammation in women with type 2 diabetes: a randomised controlled clinical trial. Br J Nutr 113:2 (2015 Jan 28), 321–330, 10.1017/S0007114514003675.
20. Liberati, A., Altman, D.G., Tetzlaff, J., Mulrow, C., Gøtzsche, P.C., Ioannidis, J.P., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62:10 (2009), e1–34, 10.1016/j.jclinepi.2009.06.006.
21. Higgins, J.P.T., Altman, D.G., Gøtzsche, P.C., Jüni, P., Moher, D., Oxman, A.D., et al., Cochrane Bias Methods Group, Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ, 343, 2011, d5928, 10.1136/bmj.d5928.
22. Schulz, K.F., Altman, D.G., Moher, D., CONSORT group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 152:11 (2010), 726–732, 10.7326/0003-4819-152-11-201006010-00232.
23. Dewulf, E.M., Cani, P.D., Claus, S.P., Fuentes, S., Puylaert, P.G., Neyrinck, A.M., et al. Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut 62:8 (2013), 1112–1121, 10.1136/gutjnl-2012-303304.
24. Salazar, N., Dewulf, E.M., Neyrinck, A.M., Bindels, L.B., Cani, P.D., Mahillon, J., et al. Inulin-type fructans modulate intestinal Bifidobacterium species populations and decrease fecal short-chain fatty acids in obese women. Clin Nutr 34:3 (2015), 501–507, 10.1016/j.clnu.2014.06.001.
25. Morel, F.B., Dai, Q., Ni, J., Thomas, D., Parnet, P., Fança-Berthon, P., α-Galacto-oligosaccharides dose-dependently reduce appetite and decrease inflammation in overweight adults. J Nutr 145:9 (2015), 2052–2059, 10.3945/jn.114.204909.
26. Eslamparast, T., Poustchi, H., Zamani, F., Sharafkhah, M., Malekzadeh, R., Hekmatdoost, A., Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr 99:9 (2014), 535–542, 10.3945/ajcn.113.068890.
27. de Luis, D.A., de la Fuente, B., Izaola, O., Aller, R., Gutiérrez, S., Morillo, M., Double blind randomized clinical trial controlled by placebo with a fos enriched cookie on saciety and cardiovascular risk factors in obese patients. Nutr Hosp 28:1 (2013), 78–85, 10.3305/nh.2013.28.1.6255.
28. Vulevic, J., Juric, A., Tzortzis, G., Gibson, G.R., A mixture of trans-galactooligosaccharides reduces markers of metabolic syndrome and modulates the fecal microbiota and immune function of overweight adults. J Nutr 143:3 (2013), 324–331, 10.3945/jn.112.166132.
29. Asemi, Z., Khorrami-Rad, A., Alizadeh, S.A., Shakeri, H., Esmaillzadeh, A., Effects of synbiotic food consumption on metabolic status of diabetic patients: a double-blind randomized cross-over controlled clinical trial. Clin Nutr 33:2 (2014), 198–203, 10.1016/j.clnu.2013.05.015.
30. Tajadadi-Ebrahimi, M., Bahmani, F., Shakeri, H., Hadaegh, H., Hijijafari, M., Abedi, F., et al. Effects of daily consumption of synbiotic bread on insulin metabolism and serum high-sensitivity C-reactive protein among diabetic patients: a double-blind, randomized, controlled clinical trial. Ann Nutr Metab 65:1 (2014), 34–41, 10.1159/000365153.
31. Cani, P.D., Neyrinck, A.M., Fava, F., Knauf, C., Burcelin, R.G., Tuohy, K.M., et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 50:11 (2007), 2374–2383, 10.1007/s00125-007-0791-0.
32. Everard, A., Lazarevic, V., Derrien, M., Girard, M., Muccioli, G.G., Neyrinck, A.M., et al. Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. Diabetes 60:11 (2011), 2775–2786, 10.2337/db11-0227.
33. Cani, P.D., Possemiers, S., Van de Wiele, T., Guiot, Y., Everard, A., Rottier, O., et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2- driven improvement of gut permeability. Gut 58:8 (2009), 1091–1103, 10.1136/gut.2008.165886.
34. Raso, G.M., Simeoli, R., Iacono, A., Santoro, A., Amero, P., Paciello, O., et al. Effects of a Lactobacillus paracasei B21060 based synbiotic on steatosis, insulin signaling and toll-like receptor expression in rats fed a high-fat diet. J Nutr Biochem 25:1 (2014), 81–90, 10.1016/j.jnutbio.2013.09.006.
35. Kellow, N.J., Coughlan, M.T., Reid, C.M., Metabolic benefits of dietary prebiotics in human subjects: a systematic review of randomised controlled trials. Br J Nutr 111:7 (2014), 1147–1161, 10.1017/S0007114513003607.
36. Amar, J., Burcelin, R., Ruidavets, J.B., Cani, P.D., Fauvel, J., Alessi, M.C., et al. Energy intake is associated with endotoxemia in apparently healthy men. Am J Clin Nutr 87:5 (2008), 1219–1223.
37. Lassenius, M.I., Pietilainen, K.H., Kaartinen, K., Pussinen, P.J., Syrjänen, J., Forsblom, C., et al., FinnDiane Study Group. Bacterial endotoxin activity in human serum is associated with dyslipidemia, insulin resistance, obesity, and chronic inflammation. Diabetes Care 34:8 (2011), 1809–1815, 10.2337/dc10-2197.
38. Pussinen, P.J., Havulinna, A.S., Lehto, M., Sundvall, J., Salomaa, V., Endotoxemia is associated with an increased risk of incident diabetes. Diabetes Care 34:2 (2011), 392–397, 10.2337/dc10-1676.
39. Moreno-Navarrete, J.M., Escote, X., Ortega, F., Serino, M., Campbell, M., Michalski, M.C., et al. A role for adipocyte-derived lipopolysaccharide-binding protein in inflammation- and obesity-associated adipose tissue dysfunction. Diabetologia 56:11 (2013), 2524–2537, 10.1007/s00125-013-3015-9.
40. Rohrer, M., Berger, M.M., Pittet, Y.K., Delodder, F., Tappy, L., Feihl, F., et al. Metabolic and physiologic effects of an endotoxin challenge in healthy obese subjects. Clin Physiol Funct Imaging 31:5 (2011), 371–375, 10.1111/j.1475-097X.2011.01026.x.
41. Cani, P.D., Everard, A., Talking microbes: when gut bacteria interact with diet and host organs. Mol Nutr Food Res 60:1 (2016), 58–66, 10.1002/mnfr.201500406.
42. Frei, R., Akdis, M., O'Mahony, L., Prebiotics, probiotics, synbiotics, and the immune system: experimental data and clinical evidence. Curr Opin Gastroenterol 31:2 (2015), 153–158, 10.1097/MOG.0000000000000151.
43. Vogt, L., Ramasamy, U., Meyer, D., Pullens, G., Venema, K., Faas, M.M., et al. Immune modulation by different types of β2→1-fructans is toll-like receptor dependent. PLoS One, 8(7), 2013, e68367, 10.1371/journal.pone.0068367.
44. Vogt, L.M., Meyer, D., Pullens, G., Faas, M.M., Venema, K., Ramasamy, U., et al. Toll-like receptor 2 activation by β2→1-fructans protects barrier function of T84 human intestinal epithelial cells in a chain length-dependent manner. J Nutr 144:7 (2014), 1002–1008, 10.3945/jn.114.191643.
45. Franco-Robles, E., López, M.G., Implication of fructans in health: immunomodulatory and antioxidant mechanisms. ScientificWorldJournal, 2015, 2015, 289267, 10.1155/2015/289267.
46. Asarat, M., Apostolopoulos, V., Vasiljevic, T., Donkor, O., Short-chain fatty acids produced by synbiotic mixtures in skim milk differentially regulate proliferation and cytokine production in peripheral blood mononuclear cells. Int J Food Sci Nutr 66:7 (2015), 755–765, 10.3109/09637486.2015.1088935.
47. Yitbarek, A., Echeverry, H., Munyaka, P., Rodriguez-Lecompte, J.C., Innate immune response of pullets fed diets supplemented with prebiotics and synbiotics. Poult Sci 94:8 (2015), 1802–1811, 10.3382/ps/pev147.
48. Chiu, W.C., Huang, Y.L., Chen, Y.L., Peng, H.C., Liao, W.H., Chuang, H.L., et al. Synbiotics reduce ethanol-induced hepatic steatosis and inflammation by improving intestinal permeability and microbiota in rats. Food Funct 6:5 (2015), 1692–1700, 10.1039/c5fo00104h.